Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving Average – Should You Sell?

Minerva Neurosciences, Inc (NASDAQ:NERV)’s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $6.20 and traded as low as $5.13. Minerva Neurosciences shares last traded at $5.18, with a volume of 157,209 shares changing hands.

Analysts Set New Price Targets

A number of research analysts recently weighed in on NERV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Friday, March 27th. HC Wainwright reiterated a “neutral” rating and issued a $7.00 target price (up from $4.00) on shares of Minerva Neurosciences in a report on Thursday, March 12th. Finally, Wall Street Zen upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $7.00.

Minerva Neurosciences Stock Down 1.0%

The stock has a 50 day simple moving average of $6.20 and a 200 day simple moving average of $4.59. The company has a market cap of $224.14 million, a price-to-earnings ratio of -0.19 and a beta of -0.19.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in shares of Minerva Neurosciences during the fourth quarter worth about $554,000. Janus Henderson Group PLC acquired a new position in shares of Minerva Neurosciences during the fourth quarter worth about $36,000. Logos Global Management LP purchased a new stake in shares of Minerva Neurosciences during the fourth quarter worth about $13,310,000. Ally Bridge Group NY LLC purchased a new stake in shares of Minerva Neurosciences during the fourth quarter worth about $6,655,000. Finally, Farallon Capital Management LLC purchased a new stake in shares of Minerva Neurosciences during the fourth quarter worth about $9,507,000. Institutional investors and hedge funds own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.